Loading stock data…
$1.18-0.07 (-5.24%)
Decoy Therapeutics Inc.
Decoy Therapeutics Inc. in the Healthcare sector is trading at $1.18 with a market capitalization of $2M. Wall Street consensus targets $3.00 (1 analysts), implying a +155.3% move over the next 12 months. The stock is currently near its 52-week low of $1.15, remaining 80.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 3 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.40M↓ | -$2.28M↑ | -$9.03M↓ | -$895,130↑ | -$965,565 |
| Net Income | -$2.37M↓ | -$2.22M↑ | -$8.98M↓ | -$873,467↑ | -$957,825 |
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverage...